Fig. 2From: FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signalingPostoperative hepatic metastasis was confirmed by enhanced CT detection, red arrow tagging primary lesion, blue arrow tagging metastatic tumor (A); follow-up assay observed that the mean time of hepatic metastasis was 23.7 ± 9.3 months for 17 of 31 pancreatic cancer patients with high FZD7 expression, while 15.8 ± 6.4 months for 6 of 11 pancreatic cancer patients with low FZD7 expression, *P < 0.05, independent Student’s t-test (B); the monthly cumulative metastasis probability of the low FZD7 expression group was lower than that of the high FZD7 expression group, P < 0.05, Kaplan–Meier analysis (C)Back to article page